论文部分内容阅读
尿激酶作为血栓溶解药物,国外已普遍用以治疗各种眼内出血,近来有人主张应大量应用。国内蔡松年也用来治疗视网膜静脉阻塞。我们应用尿激酶静脉滴注、结膜下注射或玻璃体内注射等方法,治疗视网膜玻璃体出血及炎症性玻璃体混浊,收到较好疗效。国内文献尚未见有用国产尿激酶做玻璃体内注射及治疗炎症性玻璃体混浊的报导,现介绍如下。治疗对象及注射方法将1979年8月到1980年2月半年间应用尿激酶治疗的眼科住院患者10例作为对象,进行分析,其中外伤性前房出血1例,视网膜动脉硬化症玻璃体出血1例,视网膜静脉不全阻塞1例,眼外伤玻璃体
As a thrombolytic drug, urokinase has been widely used abroad to treat intraocular hemorrhage. Recently, some people advocate that it should be used in large quantities. Cai Songnian domestic also used to treat retinal vein occlusion. We apply urokinase intravenous infusion, subconjunctival injection or intravitreal injection and other methods for the treatment of retinal vitreous hemorrhage and inflammatory vitreous opacity, received a good effect. Domestic literature has not seen useful domestic urokinase intravitreal injection and treatment of inflammatory vitreous opacity reports are presented below. Treatment object and injection method In August 1979 to February 1980 six months of urokinase treatment of ophthalmic hospitalized patients as the object, for analysis, including traumatic hyphema in 1 case, retinal atherosclerosis vitreous hemorrhage in 1 case , Retinal vein occlusion in 1 case, ocular trauma vitreous